chmp6

chmp6

Charged Multivesicular Body Protein 6 (CHMP6)

<div class="infobox infobox-gene">
<div class="infobox-header">CHMP6 — Charged Multivesicular Body Protein 6</div>

| Attribute | Value |
|-----------|-------|
| Gene Symbol | CHMP6 |
| Full Name | Charged Multivesicular Body Protein 6 |
| Chromosome | 17q25.1 |
| NCBI Gene ID | 79170 |
| OMIM | 607986 |
| Ensembl ID | ENSG00000115183 |
| UniProt ID | Q96FY2 |
| Protein Class | ESCRT-III component |
| Molecular Weight | 23 kDa |
| Subcellular Location | Endosome, cytoplasm |
| Tissue Expression | Brain, lung, testis, liver |
</div>

Overview

CHMP6 (Charged Multivesicular Body Protein 6) is a core component of the ESCRT-III (Endosomal Sorting Complex Required for Transport-III) complex, which plays essential roles in multivesicular body (MVB) formation, autophagosome maturation, and lysosomal function. This gene encodes a protein that is crucial for cellular protein homeostasis and has been implicated in the pathogenesis of neurodegenerative diseases through its roles in [endosomal sorting](/mechanisms/endosomal-sorting), [autophagy](/mechanisms/autophagy), and [lysosomal function](/mechanisms/lysosomal-dysfunction) [@hanson2012][@lee2019].

Protein Structure and Function

Structural Features

CHMP6 is a 201-amino acid protein belonging to the CHMP (Charged Multivesicular Body Protein) family:

chmp6

Charged Multivesicular Body Protein 6 (CHMP6)

<div class="infobox infobox-gene">
<div class="infobox-header">CHMP6 — Charged Multivesicular Body Protein 6</div>

| Attribute | Value |
|-----------|-------|
| Gene Symbol | CHMP6 |
| Full Name | Charged Multivesicular Body Protein 6 |
| Chromosome | 17q25.1 |
| NCBI Gene ID | 79170 |
| OMIM | 607986 |
| Ensembl ID | ENSG00000115183 |
| UniProt ID | Q96FY2 |
| Protein Class | ESCRT-III component |
| Molecular Weight | 23 kDa |
| Subcellular Location | Endosome, cytoplasm |
| Tissue Expression | Brain, lung, testis, liver |
</div>

Overview

CHMP6 (Charged Multivesicular Body Protein 6) is a core component of the ESCRT-III (Endosomal Sorting Complex Required for Transport-III) complex, which plays essential roles in multivesicular body (MVB) formation, autophagosome maturation, and lysosomal function. This gene encodes a protein that is crucial for cellular protein homeostasis and has been implicated in the pathogenesis of neurodegenerative diseases through its roles in [endosomal sorting](/mechanisms/endosomal-sorting), [autophagy](/mechanisms/autophagy), and [lysosomal function](/mechanisms/lysosomal-dysfunction) [@hanson2012][@lee2019].

Protein Structure and Function

Structural Features

CHMP6 is a 201-amino acid protein belonging to the CHMP (Charged Multivesicular Body Protein) family:

• N-terminal basic region: Membrane interaction domain
• Central helical domain: Core structural element
• C-terminal acidic region: Regulatory and interaction sites
• Polymerization interface: Enables filament formation

ESCRT-III Complex

CHMP6 functions as part of the ESCRT-III complex:

• CHMP1-5: Core ESCRT-III components
• CHMP6: Specifically involved in MVB formation
• VPS4: AAA ATPase that disassembles ESCRT-III
• ALIX: Accessory protein linking ESCRT functions

Molecular Function

CHMP6 participates in several critical cellular processes:

Role in Neurodegeneration

Endosomal Dysfunction

CHMP6 is crucial for proper endosomal sorting:

• Processes [amyloid precursor protein (APP)](/proteins/app) and its cleavage products
• Controls trafficking of [tau](/proteins/tau) and [alpha-synuclein](/proteins/alpha-synuclein)
• Prevents toxic protein accumulation
• ESCRT dysfunction leads to endosomal trafficking defects in AD and PD

Autophagy Impairment

CHMP6 plays a key role in [autophagy](/mechanisms/autophagy):

• Facilitates autophagosome-lysosome fusion
• Required for proper degradation of damaged organelles
• Involved in清除 of protein aggregates
• Loss of CHMP6 leads to accumulation of autophagic vesicles

Lysosomal Dysfunction

Proper lysosomal function depends on CHMP6:

• MVB-lysosome fusion requires ESCRT-III
• Prevents lysosomal membrane permeabilization
• Maintains lysosomal acidic pH
• Dysfunction leads to ceroid/lipofuscin accumulation

Specific Disease Mechanisms

Alzheimer's Disease

• Regulates amyloid-beta secretion and clearance
• Controls tau secretion via exosomes
• ESCRT dysfunction promotes amyloid plaque formation

Parkinson's Disease

• Facilitates alpha-synuclein degradation
• Prevents Lewy body formation
• Protects dopaminergic neurons from protein toxicity

Signaling Pathway

Expression Pattern

CHMP6 is expressed in various tissues:

| Tissue | Expression Level |
|--------|-----------------|
| Brain | High (neurons, glia) |
| Lung | Moderate |
| Testis | Moderate |
| Liver | Low-moderate |
| Kidney | Low |

In the brain, CHMP6 is expressed in:

• Neurons (especially cortical and hippocampal)
• [Astrocytes](/cell-type- [Oligodendrocytes](/cell-types/oligodendrocytes)oglia
• [Oligodendrocytes](/cell-types/oligodendrocytes)

Molecular Interactions

ESCRT Complex Partners

CHMP6 interacts with multiple ESCRT components:

• CHMP4 (both isoforms)
• CHMP5
• CHMP2
• VPS4
• ALIX

Non-ESCRT Interactions

• Autophagy-related proteins
• Ubiquitin ligases
• Trafficking adaptors

Therapeutic Implications

Targeting ESCRT Function

Modulating CHMP6 or ESCRT function represents a therapeutic approach:

| Strategy | Approach | Status |
|----------|----------|--------|
| ESCRT enhancement | Increase ESCRT expression | Research |
| VPS4 modulators | Stabilize ESCRT complexes | Development |
| Autophagy induction | Bypass ESCRT defects | Preclinical |
| Gene therapy | Deliver functional CHMP6 | Experimental |

Challenges

• ESCRT has multiple essential cellular functions
• Systemic modulation may cause adverse effects
• Achieving neuronal specificity is difficult
• Optimal timing of intervention unclear

Research Directions

Current areas of investigation include:

Molecular Mechanisms

ESCRT-III Polymerization

CHMP6 exhibits unique polymerization dynamics:

Filament formation:

• CHMP6 forms helical filaments on membrane surfaces
• Polymerization is reversible and regulated
• Filament thickness: ~10nm
• Assembly requires membrane association

• Induces inward budding of endosomal membranes
• Facilitates cargo sorting into forming vesicles
• Works in concert with other ESCRT components

Autophagy Connections

CHMP6 intersects with autophagy through multiple mechanisms:

Autophagosome-lysosome fusion:

• Required for completion of autophagy
• Facilitates membrane tethering
• Enables degradation of cargo

• Role in aggregate clearance
• Organelle turnover
• Bacterial degradation (xenophagy)

Traffic Regulation

CHMP6 coordinates multiple trafficking pathways:

Endosomal sorting:

• Cargo recognition and sequestration
• Ubiquitin-dependent sorting
• Recycling vs degradation decisions

• MVB fusion machinery
• Enzyme delivery
• Membrane protein turnover

Signaling Networks

Interactions with Other Pathways

CHMP6 function integrates with cellular signaling:

mTOR signaling:

• mTOR inhibition induces ESCRT activity
• Nutrient sensing links to trafficking
• Autophagy regulation connection

• ESCRT recognizes ubiquitinated cargo
• Deubiquitination before degradation
• Coordination with proteasome

• PI3P distribution on endosomes
• Membrane identity specification
• ESCRT recruitment signals

ESCRT Complex Dynamics

The ESCRT system functions as an integrated unit:

| Component | Function | CHMP6 Interaction |
|-----------|----------|-------------------|
| ESCRT-0 | Cargo recognition | Upstream recruitment |
| ESCRT-I | Polymer formation | Co-assembly |
| ESCRT-II | Membrane deformation | Coordination |
| ESCRT-III | Membrane scission | Direct interaction |
| VPS4 | Complex disassembly | Recycling |

Therapeutic Approaches

Modulation Strategies

Upregulation approaches:

• Increase CHMP6 expression
• Enhance ESCRT assembly
• Promote autophagic clearance

• Block excessive trafficking
• Modulate protein degradation
• Reduce exosome release

Combination Therapies

CHMP6-targeted approaches combined with:

• Autophagy enhancers
• Proteasome modulators
• Anti-aggregation strategies
• Anti-inflammatory treatments

Delivery Challenges

Targeting neuronal ESCRT:

• Blood-brain barrier penetration
• Cell-type specificity
• Avoiding systemic effects
• Achieving therapeutic concentrations

Model Systems

Research Models

| Model System | Advantages | Limitations |
|--------------|------------|-------------|
| Yeast | Genetic tractability | Evolutionary distance |
| C. elegans | In vivo trafficking | Limited toolkit |
| Drosophila | Neuronal studies | Differences from humans |
| Mammalian cells | Physiological relevance | Complexity |
| iPSC neurons | Disease modeling | Variability |

Phenotypic Readouts

Cellular phenotypes:

• MVB size and number
• Autophagosome accumulation
• Lysosomal function
• Cargo trafficking kinetics

• Locomotor function
• Neuronal survival
• Lifespan
• Behavioral outputs

Clinical Translation

Biomarker Potential

Diagnostic markers:

• ESCRT component levels in CSF
• Exosome profiles
• Genetic variant testing

• Longitudinal biomarker tracking
• Correlations with clinical measures
• Treatment response indicators

Clinical Development

Current status:

• No direct CHMP6 modulators in trials
• ESCRT biology actively investigated
• Gene therapy approaches emerging

• Small molecule development
• RNA-based therapeutics
• Protein replacement approaches

CHMP6 in Neuronal Physiology

Synaptic Function

CHMP6 plays important roles in neuronal function beyond general trafficking:

Synaptic vesicle trafficking:

• ESCRT components regulate synaptic vesicle release
• Controls presynaptic protein turnover
• Modulates neurotransmitter release kinetics

• Regulates AMPA receptor endocytosis
• Controls NMDA receptor trafficking
• Affects dendritic spine morphology

Neuronal Protein Quality Control

CHMP6 is crucial for protein homeostasis in neurons:

Aggregate clearance:

• Mediates selective autophagy of protein aggregates
• Handles misfolded protein stress
• Prevents toxic protein accumulation

• Controls synaptic receptor density
• Regulates ion channel expression
• Manages signaling complex turnover

CHMP6 in Specific Neurodegenerative Diseases

Amyotrophic Lateral Sclerosis

CHMP6 involvement in ALS:

Protein homeostasis:

• Dysregulated in ALS models
• Contributes to TDP-43 aggregation
• Affects autophagy-lysosome pathway

• ESCRT deficits in motor neurons
• Enhanced sensitivity to stress
• Links to SOD1 pathology

Frontotemporal Dementia

CHMP6 in FTD:

TDP-43 pathology:

• ESCRT dysfunction worsens TDP-43 aggregation
• Similar mechanisms to ALS
• Shared therapeutic targets

Huntington's Disease

CHMP6 in HD:

Mutant huntingtin clearance:

• ESCRT helps clear mutant huntingtin
• Autophagy impairment in HD
• Potential therapeutic target

Structural Insights

Crystal Structure

Recent structural studies have revealed:

Key structural features:

• N-terminal alpha-helical domain
• Central core structure
• C-terminal polymerization motif

• Open and closed conformations
• Polymerization-induced changes
• Membrane interaction interfaces

Structure-Function Relationships

Understanding structure enables drug development:

• Targetable interfaces
• Allosteric sites
• Polymerization inhibitors

Therapeutic Strategies

Direct Targeting

ESCRT enhancement:

• Increase CHMP6 expression
• Promote ESCRT assembly
• Enhance autophagy

Indirect Approaches

Autophagy induction:

• Bypass ESCRT defects
• Enhance lysosomal function
• Promote aggregate clearance

Gene Therapy

• AAV-CHMP6 delivery
• Cell-type specific expression
• Regulated expression systems

Biomarker Development

Diagnostic Markers

• ESCRT component levels in CSF
• Exosome profiles
• Genetic testing

Disease Progression

• Longitudinal biomarker tracking
• Treatment response indicators
• Clinical correlation studies

Research Models

In Vitro Models

| Model | Applications | Advantages |
|-------|--------------|------------|
| HEK cells | Basic mechanisms | Easy to manipulate |
| Primary neurons | Neuronal function | Physiological |
| iPSC neurons | Disease modeling | Patient-specific |

In Vivo Models

• Mouse models
• Zebrafish models
• Drosophila models

Clinical Translation

Current Status

• No CHMP6-targeted therapies in clinical trials
• Active basic research
• Preclinical development ongoing

Challenges

• ESCRT has multiple essential functions
• Achieving neuronal specificity
• Systemic vs. local delivery

Future Directions

• Small molecule modulators
• RNA-based therapies
• Gene replacement approaches

Key Publications

CHMP6 in Synaptic Function

Synaptic Vesicle Trafficking

CHMP6 plays a crucial role in synaptic vesicle cycle optimization and protein turnover at presynaptic terminals. The endosomal sorting machinery regulates synaptic vesicle protein composition by controlling the trafficking of synaptic vesicle components through the multivesicular body pathway. This process ensures that aged or damaged synaptic vesicle proteins are targeted for degradation while functional components are recycled.

The regulation of synaptic vesicle trafficking by ESCRT-III involves:

• Control of synaptic vesicle protein quality control
• Modulation of synaptic vesicle pool size
• Regulation of vesicle release probability
• Management of synaptic vesicle replenishment

Postsynaptic Receptor Trafficking

At postsynaptic sites, CHMP6 contributes to AMPA receptor (AMPAR) and NMDA receptor (NMDAR) turnover. Proper receptor trafficking is essential for synaptic plasticity, learning, and memory. ESCRT-mediated endosomal sorting controls the surface expression of these receptors, which directly impacts synaptic strength and plasticity mechanisms.

The postsynaptic functions include:

• AMPA receptor recycling and degradation
• NMDA receptor subunit composition
• Synaptic scaffolding protein turnover
• Dendritic spine morphology maintenance

Neurotransmitter Release Dynamics

CHMP6 influences neurotransmitter release through multiple mechanisms:

CHMP6 and Protein Aggregation in Neurodegeneration

Aggregate Clearance Mechanisms

Protein aggregation is a hallmark of neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and ALS. CHMP6-mediated ESCRT function is critical for clearing misfolded proteins and preventing toxic aggregate formation.

The aggregate clearance pathway involves:

• Recognition of ubiquitinated protein aggregates
• Engulfment into double-membrane autophagosomes
• Delivery to multivesicular bodies
• Fusion with lysosomes for degradation

Specific Aggregation Pathways

Alzheimer's Disease:

• Amyloid precursor protein (APP) processing and Aβ secretion
• Tau protein clearance and exosome-mediated spread
• BACE1 trafficking and amyloid plaque formation

• Alpha-synuclein degradation pathways
• Lewy body formation prevention
• Dopaminergic neuron survival mechanisms

• TDP-43 aggregation clearance
• SOD1 mutant protein clearance
• FUS protein homeostasis

Molecular Interactions Deep Dive

CHMP6 Structural Basis

The CHMP6 protein structure reveals several key functional elements:

N-terminal Membrane Interaction Domain:

• Highly basic region that binds negatively charged phospholipids
• Membrane curvature sensing capability
• Initial recruitment to endosomal membranes

• Six alpha-helices forming a helical bundle
• Dimerization interface for filament formation
• Conformational changes upon polymerization

• Acidic terminal tail regulates polymerization
• Multiple phosphorylation sites for functional control
• Interaction sites for accessory proteins

Polymerization Mechanism

CHMP6 polymerization follows a stepwise process:

CHMP6-CHMP4 Interactions

The interaction between CHMP6 and CHMP4 isoforms is crucial for ESCRT-III function:

• CHMP6 can initiate polymerization while CHMP4 completes the process
• Co-polymerization creates hybrid filaments with unique properties
• The stoichiometry affects membrane deformation efficiency
• Cross-talk allows regulation of multiple ESCRT functions

Therapeutic Development Strategies

Small Molecule Approaches

Several strategies are being developed to target CHMP6 function:

ESCRT Enhancers:

• Compounds that promote ESCRT-III assembly
• Stabilizers of functional ESCRT complexes
• Promoters of autophagosome-lysosome fusion

• ATPase activity modulators
• VPS4-CHMP6 interaction enhancers
• ESCRT recycling promoters

• mTOR-independent autophagy activators
• Lysosomal function enhancers
• Autophagic flux promoters

Gene Therapy Vectors

AAV-mediated CHMP6 delivery represents a promising approach:

• Serotypes with high neuronal tropism
• Cell-type specific promoters for targeting
• Regulated expression systems for safety
• Combination with other ESCRT components

Combination Therapies

Effective neuroprotection may require multi-target approaches:

• ESCRT enhancement with autophagy inducers
• Proteasome modulators with anti-aggregation compounds
• Anti-inflammatory agents with protein homeostasis enhancers
• Neurotrophic factors with trafficking modulators

Biomarker and Diagnostic Development

Disease Biomarkers

CHMP6 and ESCRT dysfunction markers:

• CSF ESCRT component levels
• Exosome profiles reflecting endosomal function
• Genetic variant testing for risk assessment
• Protein aggregation markers in peripheral tissues

Progression Indicators

Monitoring disease progression through:

• Longitudinal biomarker tracking in patient cohorts
• Correlation with clinical measures
• Treatment response indicators
• Prediction of therapeutic outcomes

Research Model Systems

Cell Culture Models

| Model | Applications | Advantages |
|-------|--------------|------------|
| HEK293 | Basic mechanisms | Easy transfection |
| HeLa | Pathway studies | Well-characterized |
| Primary neurons | Neuronal function | Physiologically relevant |
| iPSC neurons | Disease modeling | Patient-specific |
| Astrocytes | Glial function | CNS context |

Animal Models

Zebrafish:

• Transparent embryos for imaging
• Rapid development
• Motor neuron studies

• Powerful genetics
• Synaptic function assays
• Short lifespan

• Mammalian physiology
• Behavioral testing
• Disease modeling

Phenotypic Readouts

Assessing CHMP6 function through:

• Endosomal morphology analysis
• Autophagic flux measurements
• Protein turnover kinetics
• Synaptic function tests
• Behavioral assessments

Clinical Considerations

Patient Stratification

Identifying patients who may benefit from ESCRT-targeted therapies:

• Genetic variants affecting ESCRT function
• Biomarkers of ESCRT dysfunction
• Disease stage considerations
• Comorbidity factors

Therapeutic Windows

Determining optimal treatment timing:

• Pre-symptomatic intervention
• Early disease stages
• Advanced disease considerations
• Combination with disease-modifying therapies

Future Research Directions

Unresolved Questions

Key questions remaining in CHMP6 research:

Emerging Approaches

New research directions include:

• Single-cell proteomics to identify cell-type specific functions
• Spatial transcriptomics to map CHMP6 expression in tissue
• Cryo-EM structures of ESCRT-III assemblies
• High-throughput screening for ESCRT modulators

See Also

• [Endosomal Sorting](/mechanisms/endosomal-sorting)
• [Autophagy](/mechanisms/autophagy)
• [Lysosomal Dysfunction](/mechanisms/lysosomal-dysfunction)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [ESCRT Complex](/proteins/escript-complex)
• [Multivesicular Bodies](/mechanisms/multivesicular-bodies)
• [Protein Aggregation](/mechanisms/protein-aggregation)

External Links

• [NCBI Gene: CHMP6](https://www.ncbi.nlm.nih.gov/gene/79170)
• [UniProt: Q96FY2](https://www.uniprot.org/uniprot/Q96FY2)
• [Ensembl: ENSG00000115183](https://www.ensembl.org/Human/Gene/Summary?g=ENSG00000115183)
• [OMIM: 607986](https://www.omim.org/entry/607986)

Allen Brain Atlas Resources

• [Allen Human Brain Atlas](https://human.brain-map.org/) — Gene expression data
• [Allen Mouse Brain Atlas](https://mouse.brain-map.org/) — Gene expression in mouse brain
• [Allen Cell Type Atlas](https://celltypes.brain-map.org/) — Single-cell transcriptomics

References

Pathway Diagram

The following diagram shows the key molecular relationships involving chmp6 discovered through SciDEX knowledge graph analysis: